Mayzent 0.25 mg
Mayzent 0.25 mg is a medicine authorised by Swissmedic under authorisation number 67230. The authorisation holder is Novartis Pharma Schweiz AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 22 October 2020 and the authorisation is valid without a time limit. ATC code L04AE03 places the medicine in the group Immunosuppressants.
| Authorisation number | 67230 |
|---|---|
| Name | Mayzent 0.25 mg |
| Full name | Mayzent 0.25 mg, Filmtabletten |
| Authorisation holder | Novartis Pharma Schweiz AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | L04AE03 |
| First authorisation | 22 October 2020 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Mayzent 0.25 mg, Filmtabletten | B | 22 October 2020 |
| 2 | Mayzent 2.00 mg, Filmtabletten | B | 22 October 2020 |
| 3 | Mayzent 1.00 mg, Filmtabletten | B | 29 November 2023 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 12 | Tablette(n) | L04AE03 | 01.99.0. | B |
| 2 | 120 | Tablette(n) | L04AE03 | 01.99.0. | B |
| 3 | 28 | Tablette(n) | L04AE03 | 01.99.0. | B |
| 4 | 28 | Tablette(n) | L04AE03 | 01.99.0. | B |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Mayzent 0.25 mg authorised in Switzerland?
Yes. Mayzent 0.25 mg is authorised by Swissmedic under authorisation number 67230, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Mayzent 0.25 mg have?
Mayzent 0.25 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Mayzent 0.25 mg?
The authorisation holder is Novartis Pharma Schweiz AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.